OMNIPOD® 5:
GAME-CHANGING SIMPLICITY
Discover simplified diabetes management designed to help you live life—your way
Fuel your freedom with Omnipod 5 – the first and only tubeless, waterproof* automated insulin delivery (AID) system in Canada.
Omnipod 5 is integrated with compatible glucose sensors to automatically adjust your insulin every 5 minutes, helping to stay in range throughout the day and night.1,2,†,‡,§
The Omnipod 5 Pod can be worn for up to 3 days (72 hours) of continuous insulin delivery.
Technology that fits real life and doesn’t compromise on outcomes
"It was so convenient, so comfortable, so easy to put on. It doesn’t matter if you’re a six-year-old kid or you’re a 30-year-old professional athlete like myself, it’s going to make your life much easier."
To get a feel for what it’s like to wear a Pod, we offer a free demo Pod with no needle or insulin. Order one today to see how it fits into your lifestyle.
Omnipod 5 Automated Insulin Delivery System
Wearable and tubeless insulin pump: the Pod communicates directly with a compatible sensor
Algorithm is built into the Pod, so automated insulin delivery can continue without the handheld controller nearby.
Waterproof* means no disconnecting for water, sports, or activities.
Cloud connection for seamless access to data. Anytime. Anywhere.
Customizable glucose targets are readily adjustable by time of day.
Activity feature for times of reduced insulin needs.
Compared to multiple daily injections (MDI)
Omnipod 5 users gained an average of 5.4 more hours in range per day.4
Compared to conventional pump therapy
Omnipod 5 users gained an average of 4.2 more hours in range per day.5
Interested in Trying Out a Demo Pod?
You can request a free Pod Experience Kit.
Simply complete the Pod Experience Kit (PEK) form below and we will send you a free Pod Experience Kit (PEK)
What's included in the PEK?
- The kit includes a non-functioning & needle-free Demo Pod
- The Demo Pod can be worn almost anywhere you would give yourself an injection for up to 3 days (72 hours) without injecting or receiving insulin
- The Demo Pod gives the wearer an idea of the size, the weight, and how it is worn on the body
- The PEK also comes with a brochure that helps you understand how Omnipod® works.
The PEK does NOT include a Personal Diabetes Manager (PDM)
Please read our Privacy Policy for details on how we manage and protect your information below. We value your privacy and appreciate the trust you place in us by providing it.
Redefine what’s possible
Thousands of Canadians are redefining their type 1 diabetes management with Omnipod.
See more of their stories on our YouTube and connect with Omnipod and other Podders on Instagram, Facebook and Tik Tok.
With Omnipod, what feels impossible today can become your next great achievement tomorrow.
Max’s Omnipod Experience
In a 3-month clinical study, 3 cases of severe hypoglycaemia and 1 case of diabetic ketoacidosis (DKA) were reported in participants aged 6-70 years during Omnipod 5 System use. These cases were not related to automated insulin delivery malfunction. Reference: Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 14 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase.
*The Pod has an IP28 rating for up to 7.6 metres (25 feet) for up to 60 minutes. The Controller is not waterproof. Please consult sensor manufacturer user guide for sensor waterproof rating.
†Compatible with the Dexcom G6 and Dexcom G7 Sensors. Sensor is required for Automated Mode. Boluses for meals and corrections are still necessary. Sensors are sold separately and require a separate prescription. The Dexcom Sensors must be used with the Dexcom mobile app. The Dexcom receiver is not compatible. Devices compatible with Dexcom apps can be found at dexcom.com/compatibility. ‡Dexcom is in the process of discontinuing Dexcom G6 to focus on delivering the next generation of Sensor. Omnipod 5 will continue to support integration with Dexcom G6 for as long as this sensor remains available. For more information, please visit www.dexcom.com or contact Dexcom support.
§In Automated Mode, the Omnipod 5 algorithm uses your total daily insulin (TDI) to set a new Adaptive Basal Rate for you. Omnipod 5 User Manual.
¶It is important to keep the controller nearby to address important alerts/alarms. For more details on the Omnipod 5 system and its features, see Forlenza et al. DTT. 2021, 23(6) 410-424.
Important Safety Information
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older requiring insulin.
The Omnipod® 5 System is intended for single patient use. The Omnipod 5 System is indicated for use with NovoLog®/NovoRapid®, Humalog®/Liprolog®, Admelog®/Insulin lispro Sanofi®, Trurapi®/Insulin aspart Sanofi®, and Kirsty® U-100 insulin.
Refer to the Omnipod 5 Automated Insulin Delivery System User Guide for complete safety information including indications, contraindications, warnings, cautions, and instructions.
Warning: Omnipod 5 technology should NOT be used by anyone under the age of 2 years old. Omnipod 5 technology should also NOT be used in people who require less than 5 units of insulin per day as the safety of the technology has not been evaluated in this population.
Warning: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycaemia or hyperglycaemia.
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs 20.7%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs 33.4%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 3.64% vs. 1.17%, P<0.0001; 2.51% vs. 1.78, P=0.0456, respectively. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 2.64% vs. 1.37%, P<0.0001; 2.13% vs. 1.98%, P=0.2545, respectively.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-day standard therapy (ST) phase followed by a 3-month AID phase with Omnipod 5 system. Mean time >10.0 mmol/L or >180mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 38.4% vs. 16.9%, P<0.0001, respectively. Mean time >10.0 mmol/L or >180mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.7% vs. 33.7%, P<0.0001, respectively. Mean time <3.9 mmol/L or <70 mg/dL (12AM-<6AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.41% vs. 2.13%, P=0.0185. Mean time <3.9 mmol/L or <70 mg/dL (6AM-<12AM) as measured by CGM in children ST vs. 3-mo Omnipod 5: 3.44% vs. 2.57%, P=0.0799.
3. Wilmot E, et al. Presented at: ATTD; March 19-22, 2025; Amsterdam, NL. A 13-week randomized, parallel-group clinical trial conducted among 188 participants (age 4-70) [51% HbA1c≥ 8% (64 mmol/mol)] with type 1 diabetes in France, Belgium, and the U.K., comparing the safety and effectiveness of the Omnipod 5 System versus multiple daily injections with CGM. Time in range (70-180 mg/dL or 3.9-10mmol/L) with OP5 improved by 22% (43% MDI vs. 65% OP5, p<0.001). Time below range (<70 mg/dL or <3.9mmol/L) with OP5 was non-inferior to MDI (2.27% MDI vs. 2.56%, p=0.2). Data on file. 2025. RF-042025-00015.
4. Renard E, Weinstock RS, Aleppo G, et al. Diabetes Care. 2024;47(12):2248-2257. A 13-week randomized controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). Mean time in range (3.9-10.0 mmol/L) at 13-weeks as measured by CGM: Control = 43.8%, Omnipod 5 = 61.2%. Mean adjusted difference Omnipod 5 vs. control = 17.5%, p<0.0001.
5. OP5-003 Clinical Study Report. 2024. A 13-week randomized controlled trial conducted among 194 adults (age 18-70 years) with type 1 diabetes in France and the U.S., comparing the safety and effectiveness of the Omnipod 5 Automated Insulin Delivery (AID) System versus conventional non-AID pump therapy and CGM (control). At 13-weeks of Omnipod 5 use 130 participants were asked via a System Usability Survey (SUS) if the system was easy to use. 71.5% of participants strongly agreed and 19.2% agreed. Insulet Data on File. Claim-000284